RxDoctor Payments Data

Leighanne Meade

Family · Jacksonville, FLNPI 1992189245

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $82,453 of the $98,271 with a category attached, or 83.9%. 13 manufacturers reported payments, led by Atricure, Inc. at 51.4% of the total. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$98,271in general payments, 2019–2025

Across 259 payments — averaging $379.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$51K
  • Medical Device Business Services, Inc.$24K
  • Biosense Webster, Inc.$22K
  • Boston Scientific$926
  • Pfizer$225
  • Abiomed$144
  • plus $264 from 7 others

What the payments were for

  • Consulting fees$82,45384%
  • Travel & lodging$9,0699%
  • Food & beverage$6,7347%
  • Education$140%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,271 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$41,065
Medicare patients
248
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$204,243
XareltoRivaroxaban30$37,565
MultaqDronedarone Hcl26$23,218
EntrestoSacubitril/Valsartan16$20,854
JardianceEmpagliflozin14$20,672
Metoprolol Succinate206$2,516
Flecainide Acetate69$1,922
Amiodarone Hcl111$1,237
Atorvastatin Calcium121$943
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$923
Carvedilol105$819
Losartan Potassium100$805
Ezetimibe27$756
Amlodipine Besylate104$725
Potassium Chloride55$670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$225$204,243183 claims
Sanofi-aventis U.S. LLCMultaq$29$23,21826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →